# Biotech Daily Digest — 2026-02-07

**7 items from 3 sources**

## Summary by Source

- Endpoints News: 4 items
- Fierce Biotech: 2 items
- Regeneron Press Releases: 1 item


## Endpoints News

- **[The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more](https://endpoints.news/the-hims-vs-novo-showdown-pfizers-monthly-glp-1-data-q4-earnings-roundup-and-more/)**  
  _Sat, 07 Feb 2026 11:00:05 +0000_  
  Welcome back to another edition of Endpoints Weekly! It’s Super Bowl weekend with the Patriots and Seahawks fighting for the championship. While our many Boston-area readers are surely excited, most of us here in New ...

- **[Orphan drug tweak in US spending bill will make life easier for the FDA](https://endpoints.news/orphan-drug-tweak-in-us-spending-bill-will-make-life-easier-for-the-fda/)**  
  _Fri, 06 Feb 2026 19:10:15 +0000_  
  The FDA can continue to grant seven years of exclusivity for orphan drugs with new indications, as President Donald Trump this week signed a government funding extension that included a provision that codifies that process ...

- **[Agomab, SpyGlass cap biggest week for biotech IPOs since 2021](https://endpoints.news/agomab-spyglass-cap-biggest-week-for-biotech-ipos-since-2021/)**  
  _Fri, 06 Feb 2026 16:26:57 +0000_  
  Biotech IPOs are on the comeback trail.

 Fibrosis-focused Agomab Therapeutics and eye disease company SpyGlass Pharma will go public on Friday in respective $200 million and

- **[Biogen CEO says Alzheimer's drug Leqembi on track for continued growth](https://endpoints.news/biogen-ceo-says-alzheimers-drug-leqembi-on-track-for-continued-growth/)**  
  _Fri, 06 Feb 2026 16:11:57 +0000_  
  Biogen and Eisai's Alzheimer’s drug Leqembi appears to have reached some stable growth after a bumpy couple of years.

 Leqembi generated $134 million in fourth-quarter sales worldwide in 2025, jumping 54% from the previous year ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/genentech-cut-least-489-jobs-last-year-new-disclosure-reveals" hreflang="en">Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals</a>](https://www.fiercebiotech.com/biotech/genentech-cut-least-489-jobs-last-year-new-disclosure-reveals)**  
  _Feb 6, 2026 1:23pm_  
  On top of 348 known job cuts across the organization last year, Genentech laid off an additional 141 staffers last August that are just now being disclosed.

- **[<a href="https://www.fiercebiotech.com/biotech/uniqure-pauses-fabry-gene-therapy-dosing-2-groups-after-toxicities-emerge" hreflang="en">UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge </a>](https://www.fiercebiotech.com/biotech/uniqure-pauses-fabry-gene-therapy-dosing-2-groups-after-toxicities-emerge)**  
  _Feb 6, 2026 10:56am_  
  Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to treat the rare condition Fabry disease.


## Regeneron Press Releases

- **[EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications](https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-approved-fda-treatment)**  
  _Wed, 19 Nov 2025 16:10:00 -0500_  
  First and only FDA-approved treatment  for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TARRYTOWN, N.Y. , Nov.
